AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27759092
Drug: Mild electrical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild electrical stimulation (MES) with heat shock (HS) treatment, 4 treatments per week for 12 weeks
Trial: 27759092
Drug: Mild electrical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild electrical stimulation (MES) with heat shock (HS) treatment, 7 treatments per week for 12 weeks
Trial: 27759092
Drug: Mild electrical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild electrical stimulation (MES) with heat shock (HS) treatment (combined groups)
Trial: 27759092
Drug: Mild electrical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild electrical stimulation (MES) with heat shock (HS) treatment, 7 treatments per week
Trial: 24509965
Drug: ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ingenol mebutate 0.015% gel
Trial: 22744392
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for fungal keratitis
Trial: 12940924
Drug: Azathioprine or
RxNorm normalized name: azathioprine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine or mercaptopurine (MP) treatment
Trial: 10076125
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol combined with 50 microg gestodene
Trial: 10076125
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol combined with 25 microg gestodene
Trial: 10076125
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol combined with 25 microg gestodene (sequentially)
Trial: 10076125
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol combined with 25 microg gestodene (continuously)
Trial: 10076125
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol combined with 25 microg gestodene
Trial: 2274626
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg/day to a maximum of 200 mg/day)
Trial: 27814453
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily fluticasone (F)
Trial: 27814453
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily fluticasone plus salmeterol (F + S)
Trial: 27814453
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral montelukast (M)
Trial: 26464041
Drug: 60 ml
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 ml ropivacaine 0.375%
Trial: 26464041
Drug: 60 ml
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 ml isotonic saline
Trial: 25306116
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea and vitamin C supplements
Trial: 19304578
Drug: Larval therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larval therapy (bagged larvae, loose larvae)
Trial: 11606914
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg anti-CD11a monoclonal antibody
Trial: 9552136
Drug: Conventional pancreatic
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pancreatic enzyme replacement therapy (3 capsules of 8,000 FIP units Creon)
Trial: 9552136
Drug: High-lipase pancreatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-lipase pancreatic enzyme replacement therapy (1 capsule of 25,000 FIP units)
Trial: 7844208
Drug: 0.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/day LHRHa (Decapeptyl) for 14 days followed by 0.5 mg/day LHRHa during folliculogenesis (group A)
Trial: 7844208
Drug: 0.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/day LHRHa (Decapeptyl) for 14 days followed by 0.1 mg/day LHRHa during folliculogenesis (group B)
Trial: 29456086
Drug: Low-Dose Propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Propofol (LDP)
Trial: 27425010
Drug: Insulin-dose-adjusted HbA1c
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dose-adjusted HbA1c level
Trial: 15117578
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of liquid insulin aerosol (1.5 U/kg) with fine particle size (F) for 2 seconds
Trial: 15117578
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of liquid insulin aerosol (1.5 U/kg) with fine particle size (F) for 4 seconds
Trial: 15117578
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of liquid insulin aerosol (1.5 U/kg) with very fine particle size (VF) for 2 seconds
Trial: 15117578
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of liquid insulin aerosol (1.5 U/kg) with very fine particle size (VF) for 4 seconds
Trial: 15117578
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of regular insulin (0.15 U/kg)
Trial: 15794740
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of valsartan and captopril
Trial: 9172021
Drug: 20 cm2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 cm2 active patch delivering 50 micrograms/hr of fentanyl and a 30 cm2 placebo patch
Trial: 9172021
Drug: 30 cm2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 cm2 active patch delivering 75 micrograms/hr of fentanyl and a 20 cm2 placebo patch
Trial: 10624638
Drug: IV PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA with morphine
Trial: 3221377
Drug: Dietary salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary salt restriction (10 g to 2 g salt/day for five days)
Trial: 3221377
Drug: Salt repletion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt repletion (2 g salt/day to 20 g/day for five days)
Trial: 23439604
Drug: darapladib 40
RxNorm normalized name: Darapladib
DrugBank: Darapladib (DB06311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darapladib 40 mg
Trial: 23439604
Drug: darapladib 80
RxNorm normalized name: Darapladib
DrugBank: Darapladib (DB06311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darapladib 80 mg
Trial: 23439604
Drug: darapladib 160
RxNorm normalized name: Darapladib
DrugBank: Darapladib (DB06311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darapladib 160 mg
Trial: 16995871
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil alone (treatment A)
Trial: 16995871
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil co-administered with iron (treatment B)
Trial: 16995871
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of treatments A and B
Trial: 10417497
Drug: Fexofenadine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 80 mg, 120 mg, 180 mg
Trial: 14623537
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg)
Trial: 7590484
Drug: Toremifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (60 mg)
Trial: 2175149
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Indomethacin and Lisinopril
Trial: 29444721
Drug: Group interpersonal
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group interpersonal psychotherapy (IPT-G) delivered by lay community health workers (LCHWs), 12 sessions
Trial: 29444721
Drug: Children of
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children of caregivers who received IPT-G
Trial: 29444721
Drug: Caregivers receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregivers receiving treatment as usual (TAU)
Trial: 29444721
Drug: Caregivers receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregivers receiving IPT-G
Trial: 2054270
Drug: Levodopa/carbidopa combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa combination (Sinemet Plus)
Trial: 6357631
Drug: 0.1mg Sulprostone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1mg Sulprostone gel
Trial: 6357631
Drug: 0.5mg PGE2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg PGE2 gel
Trial: 6357631
Drug: 0.05mg Sulprostone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05mg Sulprostone gel
Trial: 22512481
Drug: Chemoradiotherapy (fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (fluorouracil 500 mg/m²/day during fractions 1 to 5 and 16 to 20 of radiotherapy, mitomycin C 12 mg/m² on day 1)
Trial: 20079760
Drug: Intervention (n=54):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (n=54): Supporters received monthly contacts from a counselor about providing effective support.
Trial: 10382786
Drug: IL-1ra at
RxNorm normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IL-1ra at a dose of 1 mg/kg/h (n = 20)
Trial: 10382786
Drug: IL-1ra at
RxNorm normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IL-1ra at a dose of 2 mg/kg/h (n = 22)
Trial: 8808137
Drug: Standard 1-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 1-mg cigarette
Trial: 25137036
Drug: trans-resveratrol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trans-resveratrol (500 mg) three times per day for 90 days
Trial: 15850121
Drug: Pen tablet
RxNorm normalized name: Pen Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pen tablet system for evaluation of hand motion control function; subjects instructed to tap 50 times with each hand.
Trial: 12418296
Drug: Enoxaparin 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.8 mg/kg, subcutaneous every 12 hours during 5 days
Trial: 12418296
Drug: Intravenous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unfractionated heparin during 5 days, by infusion
Trial: 3254762
Drug: L-alanyl-L-glutamine
RxNorm normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alanyl-L-glutamine
Trial: 3254762
Drug: Glycyl-L-tyrosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyl-L-tyrosine
Trial: 3254762
Drug: L-alanyl-L-glutamine and
RxNorm normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alanyl-L-glutamine and Glycyl-L-tyrosine
Trial: 29576126
Drug: Fused B-mode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fused B-mode and elastography videos with 0.25 ml volumes
Trial: 29576126
Drug: 0.25 ml
RxNorm normalized name: mineral oil 0.25 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml volumes
Trial: 29576126
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml volumes
Trial: 23848989
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg once weekly (QW/QW)
Trial: 23848989
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg twice weekly (BIW/QW)
Trial: 23848989
Drug: Etanercept (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (both dosing regimens)
Trial: 20557313
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg aspirin per day for 6 months
Trial: 20557313
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg aspirin per day for 6 months
Trial: 10739392
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of aspirin
Trial: 18596733
Drug: High-dose epoetin-alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epoetin-alpha
Trial: 18596733
Drug: Low-dose epoetin-alpha
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose epoetin-alpha
Trial: 16059627
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray salmon calcitonin (CT‐NS)
Trial: 11105068
Drug: Clonazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (2 mg/day)
Trial: 10235588
Drug: Bismuth plus
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth plus metronidazole and amoxicillin (group A)
Trial: 10235588
Drug: Omeprazole plus
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole plus amoxicillin (group B)
Trial: 10235588
Drug: H. pylori-positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori-positive patients post-treatment
Trial: 1472937
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose alpha 2B interferon (9 mU/week) in combination with oral chemotherapy
Trial: 1472937
Drug: Oral chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chemotherapy only (control group)
Trial: 6329567
Drug: Prednisone, azathioprine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, azathioprine, and OKT3 antibody
Trial: 29288764
Drug: Erlotinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib plus tivantinib (150 mg once daily and 360 mg twice daily)
Trial: 27567363
Drug: Nifedipine (80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (80mg daily until labor, max 18 days)
Trial: 11994701
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg twice daily)
Trial: 10934090
Drug: Zafirlukast (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast (80 mg twice daily)
Trial: 11994701
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of loratadine and zafirlukast
Trial: 11994701
Drug: Zafirlukast alone
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zafirlukast alone vs combination with loratadine
Trial: 7843449
Drug: Alpha-blocker (bunazosin)
RxNorm normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker (bunazosin) 2 mg/d for 6 months
Trial: 7843449
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets per day for 6 months)
Trial: 1903599
Drug: Enteral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral glutamine infusion at graded rates (0 to 126 mmol/h)
Trial: 1903599
Drug: Enteral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral glutamine infusion at 46.8 mmol/h
Trial: 1903599
Drug: Enteral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral glutamine infusion
Trial: 30597688
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 0.1, 0.2, 0.5, 1.0 mg/kg
Trial: 30283029
Drug: Midazolam 0.045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.045 mg/kg (active placebo)
Trial: 28768921
Drug: Evacetrapib 130
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib 130 mg daily for 12 weeks
Trial: 28768921
Drug: Placebo/atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/atorvastatin
Trial: 26105582
Drug: Fenofibrate (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (160 mg/day) for 8 weeks in obese patients without T2DM
Trial: 26105582
Drug: Fenofibrate (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (160 mg/day) for 8 weeks in obese patients with T2DM
Trial: 26105582
Drug: Fenofibrate (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (160 mg/day) and pioglitazone (15 mg/day) combination for 8 weeks in obese patients with T2DM
Trial: 24389932
Drug: Mild hyperthermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hyperthermia therapy (body core temperature 38.6 °C) combined with multimodal inpatient rehabilitation
Trial: 22464343
Drug: Rapid genotyping
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid genotyping group (CYP2C19*2 carriers treated with 10 mg prasugrel daily)
Trial: 22464343
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (CYP2C19*2 carriers treated with 75 mg clopidogrel daily)
Trial: 20703198
Drug: Fluoxetine 10-60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 10-60 mg/day for 12 weeks
Trial: 20703198
Drug: Fluoxetine continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine continuation
Trial: 15777603
Drug: Salmeterol HFA
RxNorm normalized name: Fluticasone-Salmeterol HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol HFA MDI 50 microg twice daily
Trial: 15777603
Drug: Salmeterol CFC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol CFC MDI 50 microg twice daily
Trial: 12482334
Drug: Embolization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embolization therapy with polyvinyl alcohol foam (Ivalon) as a single agent
Trial: 12482334
Drug: Chemoembolization using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoembolization using polyvinyl alcohol foam mixed with 750 mg/m2 of 5‐fluorouracil and 9 million units of interferon
Trial: 9588435
Drug: Sumatriptan injection
RxNorm normalized name: sumatriptan Injection
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan injection (6 mg)
Trial: 8575241
Drug: Indapamide treatment
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide treatment (2.5 mg)
Trial: 2243350
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg/70 kg i.m.) at 6 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Trial: 2243350
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg/70 kg i.m.) at 12 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Trial: 2243350
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg/70 kg i.m.) at 24 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Trial: 2243350
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg/70 kg i.m.) at 36 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Trial: 2243350
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg/70 kg i.m.) at 48 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Trial: 2243350
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg/70 kg i.m.) at 60 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Trial: 2243350
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg/70 kg i.m.) at 72 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Trial: 31277301
Drug: GEE extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEE extract 1000 mg/day
Trial: 27753794
Drug: Hepavax-Gene TF
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hepavax-Gene TF vaccine
Trial: 23585310
Drug: No Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Test Atorvastatin 80 mg/day (A80)
Trial: 23585310
Drug: No Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Test Pravastatin 40 mg/day (P40)
Trial: 22569014
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of epinephrine with a nasal pack soaked in 20 mL of saline for 10 minutes before surgery
Trial: 22569014
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of epinephrine with a nasal pack soaked in 20 mL of saline for 10 minutes before surgery
Trial: 19019052
Drug: Conventional expectant
RxNorm normalized name: docosahexaenoic acid Oral Capsule [Expecta]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional expectant therapy (adequate hydration, complete bed rest, and analgesics)
Trial: 17710964
Drug: Pueraria mirifica,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pueraria mirifica, oral 50 and 100 mg capsule, once daily for six months